{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:35:49Z","timestamp":1787243749863,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"DOI":"10.3389\/fcdhc.2024.1530811","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:13:50Z","timestamp":1736385230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks"],"prefix":"10.3389","volume":"5","author":[{"given":"Ioannis","family":"Ilias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zabuliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad166","article-title":"Paradigm shift in the management of metabolic diseases-next-generation incretin therapy","volume":"164","author":"Ahr\u00e9n","year":"2023","journal-title":"Endocrinology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116342","article-title":"Glucagon-like peptide-1 analogs: Miracle drugs are blooming","volume":"269","author":"Gong","year":"2024","journal-title":"Eur. J. Med. Chem"},{"key":"B3","volume-title":"One jab to treat them all","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2022.102250","article-title":"Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities","volume":"94","author":"Manavi","year":"2022","journal-title":"Neuropeptides"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108277","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"239","author":"Ferrari","year":"2022","journal-title":"Pharmacol. Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000710","article-title":"Enterohormone therapy for short bowel syndrome","volume":"29","author":"Verbiest","year":"2022","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07105-9","article-title":"The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis","volume":"37","author":"Alexander","year":"2022","journal-title":"J. Gen. Intern. Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol. Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16658","article-title":"Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease","volume":"134","author":"Tirandi","year":"2024","journal-title":"Pol. Arch. Intern. Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108647","article-title":"GLP-1 and dual GIP\/GLP-1 receptor agonists in overweight\/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now","volume":"37","author":"Muzurovi\u0107","year":"2023","journal-title":"J. Diabetes Complications"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108436","article-title":"The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study","volume":"37","author":"Bechlioulis","year":"2023","journal-title":"J. Diabetes Complications"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01615-5","article-title":"Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the eastern and southern Europe diabetes and obesity expert group","volume":"5","author":"Janez","year":"2024","journal-title":"Diabetes Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i23.2964","article-title":"Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease","volume":"30","author":"Rocho\u0144","year":"2024","journal-title":"World J. Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15524","article-title":"The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Abdelmalek","year":"2024","journal-title":"Diabetes Obes. Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"31","author":"Hong","year":"2024","journal-title":"J. BioMed. Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240730","article-title":"Incretin mimetics as potential disease modifying treatment for Alzheimer\u2019s disease","volume":"101","author":"Crook","year":"2024","journal-title":"J. Alzheimers Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"NP977","DOI":"10.1093\/asj\/sjad258","article-title":"Further research on internet searches for on- and off-label use of weight-loss medications","volume":"43","author":"Tselebis","year":"2023","journal-title":"Aesthet Surg. J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s44263-024-00095-w","article-title":"Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface","volume":"2","author":"Raubenheimer","year":"2024","journal-title":"BMC Global Public Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr. Opin. Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2024.03.012","article-title":"Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis","volume":"71","author":"Masson","year":"2024","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes. Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar","year":"2024","journal-title":"Arch. Dermatol. Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-024-00629-x","article-title":"A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment","volume":"76","author":"Tobaiqy","year":"2024","journal-title":"Pharmacol. Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108553","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms","volume":"37","author":"G\u00f3mez-Peralta","year":"2023","journal-title":"J. Diabetes Complications"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2024.1530811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:13:52Z","timestamp":1736385232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2024.1530811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":27,"alternative-id":["10.3389\/fcdhc.2024.1530811"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2024.1530811","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1530811"}}